Metformin and cancer: New applications for an old drug

Taxiarchis V. Kourelis, Robert D. Siegel

Research output: Contribution to journalReview articlepeer-review

189 Scopus citations


Metformin, one of most widely prescribed oral hypoglycemic agents, has recently received increased attention because of its potential antitumorigenic effects that are thought to be independent of its hypoglycemic effects. Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo: (1) activation of LKB1/AMPK pathway, (2) induction of cell cycle arrest and/or apoptosis, (3) inhibition of protein synthesis, (4) reduction in circulating insulin levels, (5) inhibition of the unfolded protein response (UPR), (6) activation of the immune system, and (7) eradication of cancer stem cells. There is also a growing number of evidence, mostly in the form of retrospective clinical studies that suggest that metformin may be associated with a decreased risk of developing cancer and with a better response to chemotherapy. There are currently several ongoing randomized clinical trials that incorporate metformin as an adjuvant to classic chemotherapy and aim to evaluate its potential benefits in this setting. This review highlights basic aspects of the molecular biology of metformin and summarizes new advances in basic science as well as intriguing results from recent clinical studies.

Original languageEnglish (US)
Pages (from-to)1314-1327
Number of pages14
JournalMedical Oncology
Issue number2
StatePublished - Jun 2012


  • AMPK
  • Cancer
  • Diabetes
  • Insulin
  • LKB1
  • MTOR
  • Metformin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Metformin and cancer: New applications for an old drug'. Together they form a unique fingerprint.

Cite this